Pfizer honcho details plans to boost sales

Pfizer's drug chief opened up his playbook yesterday at a San Francisco investment conference. Ian Read, president of worldwide pharmaceutical operations, confided worries about its top seller, Lipitor, which posted fewer new patient starts than anticipated recently. To turn that around, Pfizer is flogging new data on the drug--namely a study it sponsored that showed patients switching from Lipitor to generic Zocor had a 30 percent greater risk of heart attack, stroke, or death.

Exubera has the company worried, too, and for good reason. The diabetes drug was supposed to be a best-seller, but it has delivered only $4 million in sales so far. Pfizer has dispatched "diabetes educators" to buttonhole doctors and explain how to use the drug.

- read this CNBC article

Related Articles:
Pfizer's future rests with biotech. Report
Pfizer goes public with R&D pipeline. Report
Troubled Pfizer blueprints biotech venture effort. Report
Exubera becoming a big disappointment for Pfizer. Report

Free Webinar

From Patient Adherence to Manufacturing Ease - Why Softgels Make Sense for Rx

THIS WEEK: Join Thermo Fisher Scientific’s upcoming webinar to learn why softgels offer numerous benefits for Rx drug development, including enhanced bioavailability, patient compliance and easy scale-up. Register Today!

Suggested Articles

The new Community trial will first test Amgen's Otezla, Takeda's Takhzyro and UCB's zilucoplan in hospitalized patients.

Indivior faces a new lawsuit from RB, its former parent company, over a scheme to market opioid addiction therapy Suboxone Film.

A new FDA effort brings cancer drug labels to life in videotaped panels with experts, debuting its first episode on Seagen's MBC med Tukysa.